期刊文献+

肾细胞癌患者生活质量的研究现状 被引量:2

Quality of life in patients with renal cell carcinoma
在线阅读 下载PDF
导出
摘要 肾细胞癌是泌尿系统最常见的恶性肿瘤之一,易复发或转移,对化疗、放疗和免疫治疗不敏感,患者生活质量和预后受到严重影响。近年肾细胞癌患者生活质量受到关注,尤其是在生活质量评估的量表使用、手术切除的影响和靶向药物治疗的作用等方面。该文就肾癌患者生活质量的研究作一综述,为临床上肾细胞癌的生活质量提高提供有力参考和研究依据。 Renal cell carcinoma(RCC)is one of the most common malignant tumor in urological system with high recurrence and metastasis rate,relatively resistant to radiation therapy and chemotherapy,which affects the quality of life(Qo L)and prognosis of patients with RCC. In recent years,increasing attention has been paid to the research of Qo L,especially in available instruments to measure Qo L,impact of surgical removal and targeted therapy. This review includes related researches and provides reference for clinical practice in RCC treatment.
出处 《外科研究与新技术》 2015年第1期64-67,共4页 Surgical Research and New Technique
关键词 肾细胞癌 生活质量 转移性肾癌 局限性肾癌 靶向药物治疗 Renal cell carcinoma Quality of life Metastatic renal cell carcinoma Localized renal cell carcinoma Targeted therapy
作者简介 作者简介:荣海健(1990-),男,硕士研究生 通信作者:郑军华,电子信箱:zhengjh0471@sina.com
  • 相关文献

参考文献6

二级参考文献86

  • 1郭三维,董柏君,黄翼然.肾癌预后分析的研究进展[J].国际泌尿系统杂志,2006,26(3):309-315. 被引量:12
  • 2Reeves DJ,Liu CY.Treatment of metastatic renal cell carcinoma[J].Cancer Chemother Pharmacol,2009,64(1):11-25.
  • 3Rock EP,Goodman V,Jiang JX,et al.Food and Drug Administration drug approval summary:Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma[J].Oncologist,2007,12(1):107-113.
  • 4Cabebe E,Wakelee H.Sunitinib:a newly approved small-molecule inhibitor of angiogenesis[J].Drugs Today (Barc),2006,42(6):387-398.
  • 5Goodman VL,Rock EP,Dagher R,et al.Approval summary:sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma[J].Clin Cancer Res,2007,13(5):1367-1373.
  • 6Motzer RJ,Michaelson MD,Redman BG,et al.Activity of SU11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2006,24(1):16-24.
  • 7Zimmermann K,Schmittel A,Steiner U,et al.Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib[J].Oncology,2009,76(5):350-354.
  • 8Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J].N Engl J Med,2007,356(2):115-124.
  • 9Motzer RJ,Rini BI,Bukowski RM,et al.Sunitinib in patients with metastatic renal cell carcinoma[J].JAMA,2006,295(21):2516-2524.
  • 10Faivre S,Delbaldo C,Vera K,et al.Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer[J].J Clin Oncol,2006,24(1):25-35.

共引文献46

同被引文献18

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部